• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Colon Cancers - Pipeline Review, Q3 2011 - Product Image

Colon Cancers - Pipeline Review, Q3 2011

  • ID: 1863311
  • July 2011
  • 249 pages
  • Global Markets Direct

Colon Cancers - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Colon Cancer - Pipeline Review, Q3 2011', provides an overview of the Colon Cancer therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. 'Colon Cancer - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Colon Cancer.
- A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company READ MORE >



List of Tables
List of Figures
Introduction
Colon Cancers Overview
Therapeutics Development
Colon Cancers Therapeutics under Development by Companies
Colon Cancers Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Colon Cancers Therapeutics - Products under Development by Companies
Colon Cancers Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Colon Cancers Therapeutics Development
Colon Cancers - Therapeutics Assessment
Late Stage Drug Profiles
Colon Cancers Therapeutics – Drug Profile Updates
Colon Cancers Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Colon Cancers, Q3 2011
Products under Development for Colon Cancers – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
F. Hoffmann-La Roche Ltd., 2011
Kyowa Hakko Kirin Co., Ltd., 2011
Vical Incorporated, 2011
Amgen Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
Merck & Co., Inc., 2011
Takeda Pharmaceutical Company Limited, 2011
Albany Molecular Research, Inc., 2011
Labopharm Inc., 2011
Prolexys Pharmaceuticals, Inc., 2011
Bio-Path Holdings, Inc., 2011
Novartis AG, 2011
ImClone Systems Incorporated, 2011
Astellas Pharma Inc., 2011
Eisai Co., Ltd., 2011
MDRNA, Inc., 2011
Pfizer Inc., 2011
Progenics Pharmaceuticals, Inc., 2011
Enzon Pharmaceuticals, Inc., 2011
ENKAM Pharmaceuticals A/S, 2011
Access Pharmaceuticals, Inc., 2011
Alchemia Limited, 2011
EntreMed, Inc., 2011
GW Pharmaceuticals plc, 2011
Anavex Life Sciences Corp., 2011
Enzo Biochem, Inc., 2011
ImmunoCellular Therapeutics, Ltd., 2011
Insmed Incorporated, 2011
Idera Pharmaceuticals, Inc., 2011
Lorus Therapeutics Inc, 2011
Bio-Bridge Science, Inc., 2011
Bionomics Limited, 2011
Neuren Pharmaceuticals Limited, 2011
NicOx SA, 2011
Cleveland BioLabs, Inc., 2011
Oncothyreon Inc, 2011
OncoVista Innovative Therapies, Inc., 2011
Compugen Ltd., 2011
Patrys Limited, 2011
Cosmo Pharmaceuticals S.p.A, 2011
Critical Outcome Technologies Inc., 2011
Curis, Inc., 2011
Telik, Inc., 2011
Dendreon Corporation, 2011
Prima BioMed Limited, 2011
CrystalGenomics, Inc., 2011
Sareum Holdings plc, 2011
Rexahn Pharmaceuticals, Inc., 2011
Debiopharm Group, 2011
Immupharma Plc, 2011
Multimmune GmbH, 2011
Med Discovery SA, 2011
Onyvax Ltd., 2011
Indena S.p.A., 2011
InterMed Discovery GmbH, 2011
Provecs Medical GmbH, 2011
Alethia Biotherapeutics Inc., 2011
Cerulean Pharma, Inc., 2011
MacroGenics, Inc., 2011
OncoMed Pharmaceuticals, Inc., 2011
Unibioscreen S.A., 2011
AlphaVax, Inc., 2011
Azaya Therapeutics, Inc., 2011
ProNAi Therapeutics, Inc., 2011
Reata Pharmaceuticals, Inc., 2011
Affichem, 2011
Jennerex Biotherapeutics, Inc., 2011
Advenchen Laboratories, LLC, 2011
Marillion Pharmaceuticals, Inc., 2011
Pharminox Limited, 2011
Myriad Pharmaceuticals, Inc., 2011
NovaLead Pharma Pvt. Ltd., 2011
Esperance Pharmaceuticals, Inc., 2011
Xencor, Inc., 2011
Vaccinogen, Inc., 2011
Globeimmune, Inc., 2011
Etubics Corporation, 2011
Taiwan Liposome Company, 2011
Intracel Resources, LLC, 2011
AVEO Pharmaceuticals, Inc., 2011
Phytomedics, Inc., 2011
Pique Therapeutics, 2011
Cellceutix Pharmaceuticals, Inc., 2011
ISA Pharmaceuticals B.V., 2011
ImQuest Life Sciences, 2011
TAU Therapeutics, LLC, 2011
Immunovative Therapies, Ltd., 2011
Oncozyme Pharma Inc., 2011
CytomX, LLC., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Colon Cancers Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Colon Cancers, Q3 2011
Products under Development for Colon Cancers – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos